Monoclonal antibody developer Cytogen last month entered into a financing deal with Nomura SecuritiesInternational. Under the agreement, Cytogen, of Princeton, NJ,could sell up to $49 million of its common stock to Nomura fordistribution in public
Monoclonal antibody developer Cytogen last month entered into a financing deal with Nomura SecuritiesInternational. Under the agreement, Cytogen, of Princeton, NJ,could sell up to $49 million of its common stock to Nomura fordistribution in public markets. The sales will be made in a seriesof transactions over the next two years. Cytogen will use thefinancing to pursue strategic alliances and broaden its productpipeline, according to Thomas McKearn, Cytogen president and CEO.
Also last month, Cytogen announced that the Food and Drug Administrationhas accepted its product license application (PLA) for ProstaScint,a monoclonal antibody-based imaging agent for detection of prostatecancer (SCAN 2/1/95).
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.